These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16619215)

  • 1. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population.
    Yue P; Averna M; Lin X; Schonfeld G
    Hum Mutat; 2006 May; 27(5):460-6. PubMed ID: 16619215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol.
    Fasano T; Cefalù AB; Di Leo E; Noto D; Pollaccia D; Bocchi L; Valenti V; Bonardi R; Guardamagna O; Averna M; Tarugi P
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):677-81. PubMed ID: 17170371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.
    Cariou B; Ouguerram K; Zaïr Y; Guerois R; Langhi C; Kourimate S; Benoit I; Le May C; Gayet C; Belabbas K; Dufernez F; Chétiveaux M; Tarugi P; Krempf M; Benlian P; Costet P
    Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2191-7. PubMed ID: 19762784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial hypobetalipoproteinemia caused by homozygous loss-of-function mutations in PCSK9: A case report.
    Kudo T; Sasaki K; Tada H
    J Clin Lipidol; 2022; 16(5):596-600. PubMed ID: 35931648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.
    Rimbert A; Pichelin M; Lecointe S; Marrec M; Le Scouarnec S; Barrak E; Croyal M; Krempf M; Le Marec H; Redon R; Schott JJ; Magré J; Cariou B
    Atherosclerosis; 2016 Jul; 250():52-6. PubMed ID: 27179706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial hypobetalipoproteinemia in a hospital survey: genetics, metabolism and non-alcoholic fatty liver disease.
    Gutiérrez-Cirlos C; Ordóñez-Sánchez ML; Tusié-Luna MT; Patterson BW; Schonfeld G; Aguilar-Salinas CA
    Ann Hepatol; 2011; 10(2):155-64. PubMed ID: 21502677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBL.
    Yue P; Isley WL; Harris WS; Rosipal S; Akin CD; Schonfeld G
    Atherosclerosis; 2005 Jan; 178(1):107-13. PubMed ID: 15585207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four novel mutations in APOB causing heterozygous and homozygous familial hypobetalipoproteinemia.
    Whitfield AJ; Marais AD; Robertson K; Barrett PH; van Bockxmeer FM; Burnett JR
    Hum Mutat; 2003 Aug; 22(2):178. PubMed ID: 12872264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature.
    Cefalù AB; Norata GD; Ghiglioni DG; Noto D; Uboldi P; Garlaschelli K; Baragetti A; Spina R; Valenti V; Pederiva C; Riva E; Terracciano L; Zoja A; Grigore L; Averna MR; Catapano AL
    Atherosclerosis; 2015 Mar; 239(1):209-17. PubMed ID: 25618028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
    Cohen JC; Boerwinkle E; Mosley TH; Hobbs HH
    N Engl J Med; 2006 Mar; 354(12):1264-72. PubMed ID: 16554528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations.
    Aung LH; Yin RX; Miao L; Hu XJ; Yan TT; Cao XL; Wu DF; Li Q; Pan SL; Wu JZ
    Lipids Health Dis; 2011 Jan; 10():5. PubMed ID: 21232153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.
    Mayne J; Ooi TC; Raymond A; Cousins M; Bernier L; Dewpura T; Sirois F; Mbikay M; Davignon J; Chrétien M
    Lipids Health Dis; 2013 May; 12():70. PubMed ID: 23663650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.
    Mayne J; Dewpura T; Raymond A; Bernier L; Cousins M; Ooi TC; Davignon J; Seidah NG; Mbikay M; Chrétien M
    Clin Chem; 2011 Oct; 57(10):1415-23. PubMed ID: 21813713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial hypobetalipoproteinemia: analysis of three Spanish cases with two new mutations in the APOB gene.
    Martín-Morales R; García-Díaz JD; Tarugi P; González-Santos P; Saavedra-Vallejo P; Magnolo L; Mesa-Latorre JM; di Leo E; Valdivielso P
    Gene; 2013 Nov; 531(1):92-6. PubMed ID: 24001780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene.
    Tada H; Okada H; Nomura A; Nohara A; Takamura M; Kawashiri MA
    Intern Med; 2020; 59(6):783-787. PubMed ID: 32173689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.
    Cohen J; Pertsemlidis A; Kotowski IK; Graham R; Garcia CK; Hobbs HH
    Nat Genet; 2005 Feb; 37(2):161-5. PubMed ID: 15654334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
    Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
    Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ; Li JJ
    Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians.
    Tsai CW; North KE; Tin A; Haack K; Franceschini N; Saroja Voruganti V; Laston S; Zhang Y; Best LG; MacCluer JW; Beaty TH; Navas-Acien A; Kao WH; Howard BV
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E345-9. PubMed ID: 25412415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.